Background: Neoadjuvant chemoradiotherapy (CRT) is one of the preferred initial treatment strategies for locally advanced rectal cancer. Responses are variable, and most patients still require surgery. The aim of this study was to identify molecular mechanisms determining poor response to CRT.
Surgical relevance
Organ preservation is an attractive alternative in rectal cancer management following neoadjuvant chemoradiotherapy (CRT) to avoid the morbidity of radical surgery. Molecular steps associated with tumour response to CRT may provide a useful tool for the identification of patients who are candidates for no immediate surgery.
In this study, tumours resistant to CRT were more likely to have activation of specific genetic pathways that result in phosphorylated Akt (pAkt) activation. Pretreatment biopsy tissues with high immunoexpression of pAkt were more likely to exhibit a poor histological response to CRT. In addition, the introduction of a pAkt inhibitor to cancer cell lines in vitro and in vivo led to a significant improvement in sensitivity to CRT.
Identification of pAkt-activated tumours may thus allow the identification of poor responders to CRT. In addition, the concomitant use of pAkt inhibitors to increase sensitivity to CRT in patients with rectal cancer may constitute an interesting strategy for increasing the chance of a complete response to treatment and organ preservation.
Introduction
Patients with rectal cancer undergoing neoadjuvant chemoradiotherapy (CRT) may develop complete clinical regression with excellent prognosis, questioning the need for proctectomy in all patients 1 -3 . Organ-preserving approaches avoid radical surgery and its associated morbidity, mortality, functional consequences, and requirement for a temporary or definitive stoma 3 -6 . Clinical, pathological and radiological features of the primary cancer have limited ability to predict response 7 . In addition, many studies 8 -20 have attempted to identify gene expression signatures capable of predicting response to CRT. However, gene expression studies have failed to provide reproducible and clinically useful tools for the identification of patients who will benefit from CRT and organ-preserving approaches 21 . Although there is little overlap or concordance in the genes identified in these studies, common pathways involved in DNA repair, apoptosis and growth signalling provide links between them 8,10 -12,22 , and the presence of multiple gene expression alterations in single or a few molecular pathways may provide relevant information related to the mechanisms of resistance to CRT.
In the present study, global gene expression analysis was performed using RNA-Seq for next-generation sequencing, followed by pathway enrichment analysis, in pretreatment biopsies from patients showing a complete or poor clinical response to CRT. The aim was to identify molecular mechanisms determining poor response to CRT that could be explored to improve response rates to neoadjuvant therapy.
Methods

Patients and cell lines
Pretreatment biopsies from 25 patients presenting between 2006 and 2014 with non-metastatic cT2-4 N0-2 rectal adenocarcinoma within 7 cm of the anal verge were included in the study ( Table 1) . Ethical approval was granted by the local ethics committee, and patients provided written informed consent to participate.
Briefly, all patients underwent CRT with 50⋅4-54 Gy of radiation and 5-fluorouracil (5FU)-based chemotherapy. Patients were assessed 12 weeks after CRT completion by digital rectal examination, rigid proctoscopy and high-resolution pelvic MRI 23 . Patients with clinical or radiological evidence of persistent cancer were referred for immediate radical surgery (incomplete responders). Patients with no evidence of residual disease were offered a watch-and-wait strategy 24 . Patients were included in the complete response group when a clinical complete response (cCR) was achieved and sustained for at least 24 months (managed without surgery), or when a pathological complete response (pCR, or tumour regression grade (TRG) 4) was confirmed during final pathological examination after radical surgery. To avoid potential noise associated with intermediate response to CRT, only patients with a poor response to treatment (ypT status of 2 or above, ypN+, or more than 10 per cent residual cancer cells/TRG 0-2) were included in the incomplete or no-response group.
All pretreatment tumour tissue originally used for gene expression analysis was used completely for RNA extraction, leaving insufficient tissue for immunohistochemical testing. Therefore, an additional set of 50 pretreatment biopsy samples from an independent group of patients was included for validation of Akt phosphorylation (pAkt) by immunohistochemistry to investigate the association between high Akt expression and worse response to CRT ( Table 1) . TRG was used to compare patients according to pAkt immunoexpression. For statistical purposes, poor responders (TRG 0-2 according to Dworak's classification 25 ) were compared with 'good' responders .
Finally, to assess Akt activation status and the effects of Akt inhibition in the response to CRT, colorectal tumour cell lines SW480 (radioresistant) and SW48 (radiosensitive) were obtained from American Type Culture Collection (Manassas, Virginia, USA). These cell lines were cultured in accordance with manufacturer recommendations using Leibovitz's L15 medium supplemented with 10 per cent fetal bovine serum at 37 ∘ C in a non-carbon dioxide incubator. Cell line authentication testing was performed using GenePrint ® (Promega, Madison, Wisconsin, USA).
RNA-Seq, differential expression and pathway enrichment analysis
Raw RNA-Seq data analysed in the present study were generated and used for the identification of predictive gene signatures as reported in a previous report on the same patient cohort 21 . However, for the purpose of this study, patients with rectal cancer were not divided into training and validation groups as was done previously 21 . Instead, all 25 patients were analysed as a single group (16 with poor response and 9 with complete response to CRT). Raw RNA-Seq data derived from pretreatment biopsies were mapped to the reference genome and normalized as described previously 21 . Differential gene expression analysis was performed using DESeq 26 available on Bioconductor 27 . To derive a larger set of differentially expressed genes for pathway enrichment analysis, only protein-coding genes with P < 0⋅050 were considered as differently expressed, and multiple testing corrections were not applied. Gene-set enrichment analysis (GSEA) was performed to calculate the overlap between differentially expressed genes and annotated gene sets from the Molecular Signatures Database v5.0 (MSigDB; http:// software.broadinstitute.org/gsea/msigdb/index.jsp), such as Hallmark and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways.
Immunohistochemistry and western blotting
Immunohistochemistry (IHC) was performed using pAkt (Ser473) (D9E) XP ® rabbit monoclonal antibody PN 4060S (Cell Signaling Technology, Danvers, Massachusetts, USA). The best signal-to-noise ratio was validated at a primary antibody dilution of 1 : 50, as amplified with polymer peroxidase system Novolink™ (Leica Biosystems, Buffalo Grove, Illinois, USA). Two pathologists jointly semiquantitated the extension and intensity of IHC reactions, with specific notations ascribed to cell cytoplasm and cell nuclei. Akt activation was considered 'null or low' when up to 10 per cent of cells stained weakly, and 'high' when moderately or intensely stained in at least 10 per cent of cells. χ 2 statistical analysis was carried out as a contingency analysis, considering the 95 per cent c.i. Western blotting was performed using total cell extracts. Proteins were resolved on sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane, followed by primary antibody incubation using either pAkt antibody (pS473) PN 9271 (Cell Signaling Technology) or total Akt antibody PN 9272S (Cell Signalling Technology). Secondary antibody anti-IgG (GE Healthcare, Chicago, Illinois, USA) conjugated with horseradish peroxidase was used in a 1 : 3000 dilution. Protein-antibody complexes were detected using Amersham ECL Plus™ (GE Healthcare) according to the manufacturer's protocol. Step 2
Step 3
Step 4 Step 5
Fig. 1 Experimental design.
Step 1: Global gene expression analysis of pretreatment biopsies using RNA-Seq.
Step 2: Gene-set enrichment analysis using genes expressed differentially between responding and non-responding tumours.
Step 3: Immunohistochemical analysis of Akt activation in an independent set of pretreatment biopsies.
Step 4: In vitro clonogenic assays using the radioresistant SW480 cell line.
Step 5: In vivo tumour growth using the radioresistant SW480 cell line. NGS, next generation sequencing; RTK, receptor tyrosine kinase; P, phosphate; PIP 2 , phosphatidylinositol 4,5-bisphosphate; PIP 3 , phosphatidylinositol (3,4,5)-trisphosphate; PDK, phosphoinositide-dependent kinase; ILK, integrin-linked kinase; PI3K, phosphoinositide 3-kinase; PH, Pleckstrin homology; Grb2, growth factor receptor-bound protein 2; Sos, Son of Sevenless; PKB, protein kinase B; GDP, guanosine 5 ′ -diphosphate; GTP, guanosine 5 ′ -triphosphate. Overlaps were calculated using HUGO gene symbols, and significance is estimated based on the hypergeometric distribution for (k
where k is the number of differentially expressed genes intersecting the set from the Molecular Signatures Database (MSigDB), K is the number of genes in the MSigDB set, N is the total number of known gene symbols, and n is the total number of genes in the query set. DAVID, Database for Annotation, Visualization and Integrated Discovery (https://david.ncifcrf.gov/); IPA, Integrated Process Application (http://ipasoftwarellc.com/); FDR, false discovery rate; PI3K, phosphatidylinositol-3-kinase; mTor, mechanistic target of rapamycin; KEGG, Kyoto Encyclopedia of Genes and Genomes. *Probability of pathway being significantly enriched (Fisher's exact test). Table 4 Differential expression of genes belonging to the oxidative phosphorylation or phosphatidylinositol signalling pathway in tumours from patients with a poor response to neoadjuvant chemoradiotherapy
OP, oxidative phosphorylation; PI, phosphatidylinositol. *Probability of upregulation or downregulation being statistically significant (DESeq analysis).
plating, cells were treated with 2⋅5 μmol/l MK2206 (Selleck Chemicals, Houston, Texas, USA) in 0⋅01 per cent dimethyl sulphoxide and/or 5 μmol/l 5FU (Libbs Farmacêutica, São Paulo, Brazil) and irradiated using Gammacell ® 3000 equipment (Best Theratronics, Ottawa, Ontario, Canada) 1 h after treatment. For concentration-response curves, increasing radiation doses (2, 4 or 8 Gy) were employed, whereas 2 Gy was used in experiments to evaluate the radiosensitizing effect of Akt inhibition. Radiation and 5FU quantities were chosen to mimic a single dose of chemoradiation delivered to patients 28, 29 . Colony formation was quantified 15 days after treatment. Cells were fixed with 3⋅7 per cent formaldehyde, stained with crystal violet and air-dried. Colony quantification was performed with a colorimetric densitometer with absorbance measured at 595 nm on an Infinite ® 200 PRO (Tecan Group, Männedorf, Switzerland). Three independent experiments were performed in quadruplicate. Statistical analysis was performed using ANOVA with Tukey's post hoc test using GraphPad Prism ® v5.01 (GraphPad Software, San Diego, California, USA).
Mouse xenograft experiments
Both male and female BALB/c nude mice were maintained under specific pathogen-free conditions with a 12-h light-dark cycle, and ad libitum access to diet and water.
All animal experiments were approved by the institutional ethics committee for animal experimentation. Some 4 × 10 6 SW480 cells were injected subcutaneously into the For radiotherapy, 2-Gy fractions on 5 successive days were delivered to the tumour, with the rest of the body protected by specific lead shields. 5FU (40 mg/kg diluted in 100 μl phosphate-buffered saline) was injected intraperitoneally, three times over 5 days. MK2206 is an orally bioavailable allosteric inhibitor with potential antineoplastic activity; it was diluted in 30 per cent Captisol ® (Cydex Pharmaceuticals, Overland Park, Kansas, USA) and administrated orally three times over 5 days 30 . Relative tumour volume was analysed by two-way ANOVA with Bonferroni post test correction in GraphPad Prism ® v5.01. Mice were killed 15 days from the start of the treatment (10 days after completion of treatment) to allow for CRT-induced cell death, mimicking the 'resting' period after long-course CRT in clinical practice. No animal suffering was observed during treatment.
Results
Signalling pathways are altered in rectal tumours with poor response to chemoradiotherapy
Raw RNA-Seq data used in the present study were generated for the identification of predictive gene signatures as reported previously 21 . In the present work, raw RNA-Seq data were reanalysed using an entirely different (and not previously published) strategy, aiming to identify specific molecular pathways activated in tumours exhibiting poor response to CRT. A total of 350 differentially expressed genes were identified. Of these, 123 were upregulated and 199 were downregulated in tumours from poor responders ( Table S1 , supporting information). None of the baseline radiological or clinical features was significantly associated with response to CRT ( To better understand the biological mechanisms associated with poor response to CRT, GSEA was then performed to determine the overlap between differentially expressed genes and annotated gene sets from the MSigDB, such as Hallmark and KEGG pathways (Fig. 1) . Mitochondrial oxidative phosphorylation and phosphatidylinositol signalling pathways were consistently identified as significantly enriched pathways among the set of differentially expressed genes ( Table 3) .
Alterations in both pathways appear to converge to the activation of the Akt pathway in non-responding tumours 31 -34 . Akt/protein kinases B are major kinases that act downstream of PI3K. Differentially expressed genes from the phosphatidylinositol signalling pathway included ITPK1, ITPR3, PIP5K1B and PLCB3 (downregulated) and PLCB4 and CDIPT (upregulated) in patients with poor response to CRT ( Table 4) . As represented in Fig. 2 , the suggested sequence of events culminates in Akt activation as follows: downregulation of PIP5K and/or upregulation of phosphatidylinositol synthase in non-responding tumours may increase the concentration of phosphatidylinositol 3,4-bisphosphate by lowering the conversion of phosphatidylinositol 4-phosphate to phosphatidylinositol 4,5-bisphosphate. Increased levels of phosphatidylinositol 3,4-bisphosphate, in turn, may result in direct activation of the Akt pathway.
Differentially expressed genes involved in mitochondrial oxidative phosphorylation that may also converge to Akt activation among poor responders to CRT include: ND4, ND5, Ndufs2 and Ndufv1 from complex I of the mitochondrial respiratory chain; CYTB from complex II; COX1, COX3, COX6B1 and COX15 from complex III; and ATP5B and ATP6 from complex V ( Table 4 ). All of these genes, with the exception of COX6B1, are downregulated in tumours from poor responders, suggesting that lower activity in mitochondrial oxidative phosphorylation may also play a role in poor response to CRT. Defects in mitochondrial oxidative phosphorylation, in turn, have been reported to promote activation of the Akt survival pathway through redox-mediated PTEN inactivation 33 .
The gene expression and GSEA analyses thus demonstrated that mitochondrial oxidative phosphorylation and phosphatidylinositol signalling pathways are consistently altered in rectal tumours with poor response to CRT, possibly converging to activation of the Akt survival pathway in these patients. 
Akt activation is associated with poor response to chemoradiotherapy
To confirm the association between activation of the Akt survival pathway and poor response to CRT, Akt phosphorylation at S473 (pAkt S473) was assessed as an indicative of Akt activation in an independent set of 50 pretreatment biopsies from patients with rectal cancer (Fig. 1) . As indicated in Fig. 3d , high immunoexpression of pAkt S473 (and therefore Akt activation) occurred in 75 per cent of patients with a poor histological response (TRG 0-2) to CRT. In contrast, only 48 per cent of patients who developed a good or complete histological response (TRG 3-4) showed high immunoexpression of pAkt S473 (P = 0⋅016). None of the remaining baseline radiological or clinical features was significantly associated with response to CRT ( Table 2) .
The presence of active Akt in the nucleus has been associated with direct impairment of the apoptotic cascade and activation of DNA repair mechanisms leading to tumour progression 35 . When only nuclear pAkt S473 was assessed, the present authors were also able to discriminate patients who had a poor response to CRT. High immunoexpression of nuclear pAkt S473 (samples with more than 20 per cent of nuclear pAkt) was more common among patients with a poor response (TRG 0-2) when compared with patients with a good or complete response (TRG 3-4) to CRT (48 versus 28 per cent respectively; P = 0⋅026) (Fig. 3e) .
Altogether, these results indicate that activation of the Akt pathway is frequently observed in pretreatment biopsy samples from patients with a poor response to CRT, and that activation of this important tumour cell survival pathway may contribute to radioresistance in rectal cancer.
Activation of the Akt survival pathway contributes to radioresistance in colorectal cancer cell lines
To address the role of Akt activation in radioresistance, Akt activation was analysed in two colorectal cancer cell lines known to differ in radiosensitivity profiles 36, 37 (Fig. 4) . Differences in radiosensitivity between SW48 (radiosensitive) and SW480 (radioresistant) colorectal cancer cell lines were confirmed using clonogenic assays and increasing radiation doses (2 to 8 Gy). Radiation dose-response is shown in Fig. 4a and, as expected, significant differences in the fraction of surviving cells exposed to increasing doses of radiation were observed between both cell lines. Akt phosphorylation was assessed at S473 (pAkt S473) in both cell lines as an indication of Akt activation. Akt phosphorylation (and therefore Akt activation) at S473 was detected only in the radioresistant SW480 cell line (Fig. 4b) . The SW480 cell line was treated with the allosteric Akt inhibitor MK2206 to reverse Akt activation, and cell survival was measured using clonogenic assays after exposing them to 5 μmol/l 5FU and 2 Gy radiation to mimic neoadjuvant treatment used in patients with rectal cancer (Fig. 4) . As shown in Fig. 4c , MK2206 completely inhibited Akt phosphorylation at nanomolar concentrations. As expected, no significant difference in the fraction of surviving cells was observed when SW480 radioresistant cells were exposed to radiation alone or radiation in combination with 5FU (Fig. 5a) . However, a reduction of more than 50 per cent in the survival fraction was observed when SW480 cells were treated with subdoses of MK2206 (2⋅5 μmol/l when half maximal inhibitory concentration (IC50) is 4⋅5 μmol/l) (Fig. S1 , supporting information) in combination with 2 Gy radiation plus 5FU, or with radiation alone (Fig. 5a) . Interestingly, no significant differences were observed when cells were treated with MK2206 in combination with 2 Gy radiation and 5FU, or with radiation alone, indicating that the radiosensitizing effect of MK2206 in vitro is equivalent to that of 5FU (Fig. 5a) .
Altogether, these results demonstrate that activation of the Akt survival pathway contributes to radioresistance in colorectal cancer cell lines, and suggest that Akt inhibitors may be used to radiosensitize resistant tumour cells and improve response to CRT.
Akt inhibitor MK2206 improves response to chemoradiotherapy in vivo
Finally, to explore the radiosensitizing effects of Akt inhibition in vivo, xenograft tumours were generated by injecting SW480 radioresistant cells subcutaneously into the flanks of BALB/c nude mice (Fig. 1) . Once tumours reached a volume of approximately 100 mm 3 , animals were treated daily with 2 Gy radiation for 5 consecutive days with concomitant 5FU (40 mg/kg) and/or MK2206 (120 mg/kg) given three times during the 5 days of radiotherapy, followed by an interval of 10 days (Fig. 5b) . The treatment scheme was conceived to reproduce the CRT treatment offered to patients with rectal cancer. Relative tumour volume was measured every 3 days on average, after starting the treatment.
Treatment with radiation in combination with 5FU or treatment with MK2206 alone had little effect on the growth of xenograft tumours. In contrast, the combination of radiation, 5FU and MK2206 resulted in a reduction in tumour growth, which reached statistical significance 15 days after the start of treatment (Fig. 5b) . Tumours from animals treated with radiation in combination with 5FU and MK2206 grew much slower throughout the experiment and were on average 50 per cent smaller relative to tumours from control groups at 15 days.
These results suggest that Akt inhibitors can radiosensitize originally resistant tumour cells in vivo and improve response to CRT in a preclinical mouse model.
Discussion
Even though development of cPR to CRT may not be equivalent to cure of the disease, patients with a complete response seem to be appropriate candidates to avoid major surgery, with improved functional and similar oncological outcomes 3 -5,38 . Thus, enhancement of response to CRT would potentially allow an increase in the proportion of patients that might be offered organ preservation by avoiding unnecessary definitive radical surgery.
Here, mitochondrial oxidative phosphorylation and phosphatidylinositol signalling pathways were shown to be consistently altered in rectal tumours with poor response to CRT. Molecular alterations leading to activation of the phosphatidylinositol-3-kinase PI3K pathway, including IGF2 overexpression, PTEN deletions and PIK3CA, K-RAS and N-RAS mutations, are known to occur in more than 40 per cent of colorectal tumours, and have well established roles in tumour progression and therapy response 39 . To a lesser extent, alterations in the expression of the components of the oxidative phosphorylation chain have also been reported in colorectal cancer 40, 41 . Altered mitochondrial function has already been associated with radioresistance in oesophageal adenocarcinoma 42 , but an association between radioresistance and alterations in the mitochondrial oxidative phosphorylation in rectal cancer is a new finding.
Alterations in mitochondrial oxidative phosphorylation and phosphatidylinositol signalling pathways appear to result in the Akt survival pathway in patients with a poor response to CRT. This hypothesis was confirmed by assessing Akt phosphorylation in pretreatment biopsies in an independent set of patients with rectal cancer submitted to CRT. Even though these findings may have limited clinical relevance for the selection of patients more likely to respond completely to CRT, they provide further evidence (in an independent sample of patients) that Akt activation correlates with worse histological response to CRT.
Akt activation controls a variety of cellular functions, including proliferation, invasion, angiogenesis and cell survival. Modulation of Akt activity is, therefore, regarded as an attractive therapeutic strategy. An analysis of 12 cancer types conducted by The Cancer Genome Atlas led to a functional subclassification of these tumours based on distinct oncogenic mechanisms and selective functional events that are eventually targetable from the therapeutic point of view. Among the five major subclasses of tumour, Akt inhibition was present in three, suggesting the relevance of this pathway to the development and maintenance of multiple tumour types, including colorectal tumours 43 .
Although some clinical trials using different Akt inhibitors for several solid cancer types have shown good results 44 -46 , with tolerable toxicity, there is still a consensus that Akt inhibitors should be administered in combination with radiotherapy and chemotherapy 47 . In this context, Akt inhibitors were found to radiosensitize resistant tumour cells in vitro and in vivo, and improve the response to CRT by 50 per cent in a preclinical mouse model. These observations support the use of Akt inhibitors in a multimodality treatment setting for the management of rectal cancer. Indeed, a phase I clinical trial using nelfinavir as an Akt inhibitor in combination with CRT in rectal cancer resulted in an improved response, and supported a phase II study to explore these clinical outcomes further 48 .
Sample size is certainly one of the major limitations of this work. Challenges in optimal biological tissue collection, matched high-quality clinical data and cost of molecular analysis may have contributed to this limitation. In addition, direct comparison of MK2206 with 5FU in the setting of radiotherapy may provide further evidence for the exact mechanisms and clinical possibilities of this alternative regimen.
